. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: Nanomedicine. 2015 Aug 15;11(8):1893–1907. doi: 10.1016/j.nano.2015.07.015

Table 2.

Examples of nanoparticle formulations currently in clinical trials.

Formulation	Description	Size (nm)	In clinical trials for
Lipusu	Liposomal formulation of paclitaxel	Not available	Metastatic breast cancer (Phase IV, NCT02142790), advanced solid tumors (Phase IV, NCT01994031).
MCC-465	Targeted liposomal formulation of doxorubicin	143	Metastatic stomach cancer (Phase I/II in Japan).
SGT-53	Targeted liposomal formulation of p53 gene	115	Solid tumors (Phase I, NCT00470613), metastatic pancreatic cancer (Phase II, NCT02340117), refractory or recurrent solid tumors (Phase I, NCT02354547), recurrent glioblastoma (Phase II, NCT02354547).
PICN	Paclitaxel injection concentrate for nanodispersion	100	Metastatic or recurrent breast cancer (phase I, NCT02136927), solid tumors in advanced stages (Phase I, NCT01305512, NCT01304303).
MM-398	Liposomal formulation of irinotecan	100	Gastric or gastro-esophageal junction adenocarcinoma (Phase II ⁴⁴), pediatric solid tumors (Phase I, NCT02013336), various breast cancers (Phase I, NCT01770353), high grade gliomas (Phase I, NCT02022644).
TIL	Liposomal formulation of topotecan	100	Small cell lung cancer, ovarian cancer, other advanced tumors (Phase I, NCT00765973).
VIL	Liposomal formulation of vinorelbine	100	Advanced solid tumors (Phase I, NCT00364676).
Thermodox	Heat-activated liposomal formulation of doxorubicin	100	Liver cancer (Phase III, NCT00617981, NCT02112656, Phase I, NCT02181075), breast cancer (Phase I/II, NCT00826085).
LiPlaCis	Liposomal formulation of cisplatin	Not available	Advanced or refractory solid tumors (Phase I, NCT01861496).
BIND-014	Targeted polymeric nanoparticle containing docetaxel	100	Prostate cancer (Phase II, NCT01812746, ⁴¹) and non-small cell lung cancer (Phase II, NCT01792479).
NK105	Micellar polymeric nanoparticle incorporating paclitaxel	85	Metastatic or recurrent breast cancer (Phase III, NCT01644890).
TKM- 080301	Liposomal formulation of PLK1 siRNA	80	Neuroendocrine tumors, Adrenocortical carcinoma (Phase I/II, NCT01262235).
Atu027	Liposomal formulation of PKN3 siRNA	Not Available	Advanced or metastatic pancreatic cancer (Phase I/II, NCT01808638).
CALAA-01	Targeted polymeric nanoparticle containing gene silencing RNA	75	Various cancers (Phase I ⁴⁵).
NC-6300	Micellar polymeric nanoparticle incorporating epirubicin	40–80	Various cancers (Phase I, in Japan)
NC-4016	Micellar polymeric nanoparticle incorporating oxaliplatin	40	Advanced solid tumors or lymphomas (Phase I, NCT01999491).
CRLX101	Cyclodextrin-containing polymer conjugated to camptothecin	30–40	Recurrent non-small cell lung cancer (Phase II, NCT01803269), metastatic renal cell carcinoma (Phase II, NCT02187302), ovarian/tubal/peritoneal cancer (Phase II, NCT01652079, Phase I, NCT02389985), rectal cancer (Phase I/II, NCT02010567).
Genexol-PM	Micellar polymeric nanoparticle incorporating paclitaxel	20–50	Metastatic breast cancer (Phase II, NCT01784120), head and neck cancer (Phase II, NCT01689194).
NC-6004	Micellar polymeric nanoparticle incorporating cispatlin	20	Locally advanced or metastatic pancreatic cancer (Phase III, NCT02043288) and non-small cell lung cancer (Phase I/II, NCT02240238).